Poznámky k epizodě
With the advent of GLP-1 drugs, it was only a matter of time before Brad and Gabriel dove into a discussion about this controversial drug class and the equally contentious disease, obesity. In this episode, they explore a range of topics—from the history of obesity and its recognition as a disease to how GLP-1s like Ozempic are influencing the conversation around the legitimacy and stigma of obesity beyond just Body Mass Index (BMI). One of the most compelling ideas from this thought-provokin...

